Back to top
more

Prothena (PRTA)

(Delayed Data from NSDQ)

$24.79 USD

24.79
541,580

+0.82 (3.42%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $24.78 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss

Prothena's (PRTA) wider-than-expected loss in the first quarter was disappointing. Sales also missed estimates by a huge margin.

    Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength

    Celgene (CELG) surpasses both earnings and sales estimates in the first quarter on the back of impressive performance from Pomalyst and Otezla.

      What's in Store for Prothena (PRTA) This Earnings Season?

      Prothena (PRTA) has faced quite a few setbacks in the year so far and hence investors will be focused on management's strategy when it reports first-quarter results next week.

        Implied Volatility Surging for Prothena (PRTA) Stock Options

        Prothena (PRTA) needs investors to pay close attention to the stock based on moves in the options market lately.

          Acorda Files Parkinson's Drug Marketing Application in EU

          Acorda Therapeutics (ACOR) is seeking approval of its Parkinson's disease candidate, Inbrija, in Europe for the treatment of symptoms of OFF periods.

            Prothena Rallies on Multi-Year Collaboration With Celgene

            Shares of Prothena (PRTA) surged significantly after the company announced a multi-year collaboration with leading company Celgene to develop new therapies for a broad range of neurodegenerative diseases.

              Options Traders Expect Huge Moves in Prothena (PRTA) Stock

              Investors in Prothena (PRTA) need to pay close attention to the stock based on moves in the options market lately.

                Prothena (PRTA) Up 8.7% Since Earnings Report: Can It Continue?

                Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  FDA Accepts Acorda's NDA for Parkinson's Disease Candidate

                  FDA accepts Acorda's (ACOR) new drug application (NDA) for its parkinson's disease candidate, Inbrija and it also set an action date of Oct 5, 2018.

                    Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses

                    Prothena (PRTA) reported a narrower-than-expected loss in the fourth quarter as the company continued with its pipeline progress.

                      Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?

                      Although Prothena's (PRTA) track record is good, the company is unlikely to beat estimates in the current quarter given the unfavorable rank and Earnings ESP.

                        Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead?

                        Prothena's (PRTA) stock tumbles more than 18% due to a pipeline setback. The company depends heavily on the success of its two candidates.

                          Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija

                          Acorda (ACOR) resubmits new drug application for its late stage pipeline candidate, Inbrija to the FDA.

                            Acorda Stock Up Despite Phase III Trial on Tozadenant Stops

                            Acorda (ACOR) decides to suspend the phase III study on tozadenant based on new data obtained from the trial, spotting comprise with patient's safety.

                              Acorda Reports Death in Parkinson's Trials, Stock Down 40%

                              Acorda's (ACOR) shares slump significantly after the company complains of safety issues related to a late-stage study on tozadenant, a lead Parkinson's disease candidate.

                                Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus

                                Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.

                                  What's in the Cards for Prothena (PRTA) in Q3 Earnings?

                                  Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.

                                    Prothena's Psoriasis Candidate Disappoints in Phase I Study

                                    Prothena Corporation plc (PRTA) announced disappointing results from a phase Ib study of pipeline candidate, PRX003 in psoriasis patients.

                                      AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug

                                      AstraZeneca (AZN) and Takeda Pharmaceutical Company entered into an agreement to jointly develop and commercialize MEDI1341 for the potential treatment of Parkinson's disease.

                                        Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment

                                        Prothena Corporation plc (PRTA) reported a narrower-than-expected loss in the second quarter as the company received a milestone payment from Roche.

                                          Should You Buy Prothena Corporation PLC (PRTA) Ahead of Earnings?

                                          Given that Prothena Corporation PLC (PRTA) has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings.

                                            Can Prothena (PRTA) Deliver a Beat this Earnings Season?

                                            Prothena Corporation plc (PRTA) is expected to report second-quarter results next week and we expect investor focus on pipeline updates.

                                              Prothena (PRTA) Down 5.8% Since Earnings Report: Can It Rebound?

                                              Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View

                                                Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.

                                                  What to Expect from Prothena (PRTA) This Earnings Season?

                                                  Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.